A case report of primary osteosarcoma originating from kidney

Changkun Huang, MD, Xuan Zhu, MD, PhD, Wei Xiong, MD, PhD, Xiaokun Zhao, MD, PhD, Ran Xu, MD, PhD*

Abstract

Rationale: Primary osteosarcoma of the kidney is a very rare subtype of renal neoplasms. There are only 27 cases reported in the literature since 1936. In addition, it has a high risk of metastasis and very low survival rate.

Patient’s concerns: In this report, we present a case of unique large osteosarcoma originated from the left kidney (21 cm × 11 cm) with lung metastasis. A 48-year-old female patient presented with intermittent abdominal distension and gross hematuria.

Diagnoses: A computed tomography scan of the abdomen confirmed a large solid, partly calcified mass in the left retroperitoneum, with lung metastasis (IV stage according to AJCC). The radical nephrectomy was performed. The postoperation immunohistochemical analysis supporting the diagnosis of osteosarcoma.

Interventions: The patient received chemotherapy with ifosfamide, cisplatinum, pirarubicin and then target therapy with anlotinib (12 mg per day, per os; days 1–14; 21 days per cycle) after surgery.

Outcomes: The patient was followed up for 26 months, with no postoperative complications, no tumor recurrence, and no progress in pulmonary metastasis.

Lessons: The case reported here is a unique large osteosarcoma originated from the kidney (21 cm × 18 cm × 11 cm) at an advanced stage (IV). However, the patient’s condition was controlled for at least 26 months after surgical resection and postoperative chemotherapy, which had never been reported in the literature before. Additionally, 3 mutated genes were found in the tissue by genetic testing, which we suspect that is the reason why this patient is sensitive to chemotherapy and thus has longer survival.

Abbreviations: FDG = fluoro-deoxy-D-glucose, HE = hematoxylin-eosin, PET-CT = Positron emission tomography–computed tomography, RCC = renal cell carcinoma, VIM = vimentin.

Keywords: fluoro-deoxy-D-glucose, oncogene, renal sarcoma, soft tissue sarcoma, urologic neoplasms

1. Introduction

Extraskeletal osteosarcoma is a very rare disease and accounts for approximately 1% of all soft tissue sarcomas and <4% of all osteosarcomas.[1] A few extraskeletal osteogenic sarcomas have been reported in the literature, but the involvement of the kidney was rare. The incidence of primary osteosarcoma in the kidney is extremely rare. Only 27 cases have been reported in the literature since 1936. Given the aggressive nature of these tumors, the overall prognosis is very poor. The rate of local recurrence, as well as distant metastasis, is approximately 86% (24/28), which is very high, with approximately 32% (9/28) of patients presenting with metastasis when diagnosed (including our case).[1–24] Here, we present a case of primary osteosarcoma of the kidney and review its clinical presentation, diagnosis, and treatment options.

2. Case reports

A 48-year-old female patient presented with a 6-month history of intermittent abdominal distension and 2 months of gross hematuria for the first time in July 2016. Abdominal physical examination revealed a left mass in the hypochondrium and iliac fossa. The rest of the physical examination showed no significant abnormalities.

Routine urine tests revealed an elevated number of red blood cells displaying homogeneity. Routine blood examination indicated anemia. Other biochemical profiles were within normal limits, except for a markedly elevated serum alkaline phosphatase levels at 1800 IU/L. Urinary cytology did not detect any malignant cells.

A computed tomography (CT) scan of the abdomen confirmed a large solid, partly calcified mass in the left retroperitoneum with the lumbar muscle infiltrated and closely related to the abdominal aorta (Fig. 1A and B). The maximum diameter was 18 cm, and there were patchy low-density lesions and calcification foci, with no enlarged lymph nodes. The source of the mass was considered to be the kidney. The nuclear bone
scan was normal. $^{18}$F-fluorodeoxyglucose Positron emission tomography–computed tomography (PET-CT) for the whole body shows that the glucose metabolism is slightly higher in the right lower lung and a metastatic tumor is considered to be present (Fig. 1C and D). From the abovementioned information, we preoperatively diagnosed this mass to be a large renal cell carcinoma featuring calcifications with lung metastasis. This patient is at stage IV according to the AJCC cancer staging manual.[25] After communicating with the patient’s family, we made an MDT (multiple disciplinary team) treatment plan that included the Department of Urology, Vascular Surgery, Oncology and CT center. The details of the plan are as follows: the radical nephrectomy will be performed by the Department of Urology and Vascular surgery and the patient will receive chemotherapy or radiotherapy after surgery according to the results of the pathology examination.

After gross examination, the kidney revealed a 21-cm x 18-cm x 11-cm large tumor replacing the kidney (Fig. 2A). The surface cut showed central yellow-brownish, rock-hard masses with areas of hemorrhage and necrosis (Fig. 2B). The tumor specimens were subjected to pathological examination. Microscopic examination of the hematoxylin–eosin stain demonstrated a diffuse arrangement of different sizes of spindle cell proliferation with interspersed osteoid of variable calcification (Fig. 3A and B). No sections had malignant epithelial elements. The resected ureteric margin failed to find any evidence of a tumor. The immunohistochemical analysis was positive for vimentin (VIM), SAM, Ki67, and CD10 and negative for renal clear cell carcinoma (RCC) and CK, supporting the diagnosis of osteosarcoma. Genetic tests showed 3 variants (MSH6, FANCF, and ERCC4) identified among 124 genes tested.

The patient had an uneventful postoperative recovery and was transferred to the Department of Oncology to receive chemotherapy. While in the Oncology Department, the patient received 5 rounds of chemotherapy with ifosfamide, cisplatinum, and pirarubicin and then received target therapy with anlotinib (12 mg per day, per os; days 1–14; 21 days per cycle) until currently. The patient exhibited a good prognosis at 26 months of follow-up, with no evidence of local recurrence and no worsening of the lesion in the lung. The patient provided informed consent for the publication of her clinical and radiological data.

3. Discussion

The clinicopathological features of 28 cases including our case are summarized in Table 1. The data suggest that the male-to-female ratio is 4:3; the age ranges from 29 to 82 (median age = 59); the left-to-right ratio is 17:10, with 1 unclear case. Flank pain and hematuria seem to be the most common complaint, followed by weight loss and some symptoms of the digestive tract. This is
different from RCC, in which flank pain is not the usual dominant complaint.\cite{29}

Osteosarcoma originating in the kidney is aggressively growing and extremely fatal; it easily infiltrates contiguous structures and metastasizes. It is most commonly seen in the adrenal gland, spleen, liver, and lungs. Approximately 24 of the 28 (86\%) patients present distant metastasis or the infiltration of contiguous organs. The average overall survival (OS) is approximately 10 months; this is likely because of their advanced stage when they are presented. Biochemical blood test results are often normal except for the serum level of alkaline phosphatase, which may help to diagnose or monitor recurrence. The “sunburst” appearance is relatively characteristic on a CT scan.

Given that RCC is the most common renal tumor diagnosed, it is crucial to distinguish the ossification of RCC from primary renal osteosarcoma. First, metaplastic bone formation in RCC is very rare; second, the absence of carcinoma is vital in diagnosing primary osteogenic sarcoma instead of RCC with ossification; third, they have different histologic origins, in which RCC comes from the epithelium while osteosarcoma originates in the mesenchyme. Immunohistochemistry helps to identify the histologic origin (such as positive for VIM, S100, SMA, and Ki67; negative for CK, RCC, and EMA).

The exact histogenesis of osteosarcoma of the kidney remains unclear. According to Virchow’s theory, first proposed in 1884 and still prevailing today, in certain circumstances, there is a metaplastic transformation of the connective tissue to embryonic mesenchyme with the ability to differentiate into osteoblasts and bones.\cite{30} The spindle cell sarcomatous status in the osteogenic areas, as noted in our case and most in the literature, tends to support this concept.

We performed genetic testing on this patient after surgery including 124 common tumor-associated genes and found that 3 genes (MSH6, FANCF, and ERCC4) had variations. These variants are expected to result in the loss of functions of the protein products from the genes. The gene-related tumor spectrum of MSH6 includes colorectal, endometrial, ovarian, and other cancers.\cite{31} Jentsch et al reported that significantly
## Table 1

Overview of the cases reported in the literature.

| Reference | Age/gender/side | Presenting symptoms | Risk factors/pertinent history | Treatment | Outcome | Tumor size | Metastases | AJCC stage | Biochemical profile |
|-----------|----------------|---------------------|---------------------------------|-----------|---------|-----------|------------|------------|-------------------|
| Huang et al. (1936) | 76/M/L | Hematuria | None known | None | Not mentioned | Not mentioned | Liver, bowel, and right kidney | IV |
| Hamer and Wishard (1948) | 52/F/L | Flank pain, hematuria, and loss of weight | None known | Radical nephrectomy | Died 4 months after surgery | 15 cm x 14 cm x 9 cm | Lungs, liver, and omentum | IV |
| Johnson et al. (1956) | 82/M/L | Flank pain | None known | Radical nephrectomy | Died 67 days after surgery | 5 cm x 4 cm | Local metastasis | II |
| Vanel et al. (1965) | 82/F/L | Flank pain, gross hematuria, and loss of weight | None known | Radical nephrectomy | Died 1 year after tumor discovered | 15 cm x 14 cm x 9 cm | Lungs, liver, and omentum | IV |
| Johnson et al. (1970) | 67/M/R | Physical examination | None known | Radical nephrectomy | Died 8 months after surgery | 12 cm x 16 cm x 10 cm | Pancreas | II B |
| Micolonghi et al. (1984) | 48/F/R | Flank pain | None known | Laparotomy + chemotherapy (vincristine, methotrexate, citrovorum and doxorubicin) | Died 4 weeks after surgery | 12.5 cm | Lungs metastasis, 7 months after surgery | IA |
| Watson et al. (1995) | 56/M/L | Flank pain and gross hematuria | None known | Radical nephrectomy | Died 18 months after surgery | 12 cm x 9 cm x 9 cm | Left adrenal gland | IB |
| Leventis et al. (1997) | 56/M/L | Flank pain | None known | Radical nephrectomy | Died 4 months after surgery | 15 cm x 9 cm x 8 cm | Lungs metastasis, 6 weeks after surgery | IB |
| Leggio et al. (2006) | 60/M/L | Abdominal pain | Hypertension, smoking | Radical nephrectomy | Died 8 months after surgery | 12 cm | Local metastases, 7 months after surgery | IB |
| Tommaso et al. (2007) | 79/M/L | Abdominal pain, weakness, and weight loss | None known | Radical nephrectomy + radiation therapy | Died 7 months after surgery | 22 cm x 16 cm | Local recurrence and distant metastasis to diaphragm, pleura and ribs, 3 months after surgery | IB |
| Puri et al. (2012) | 65/F/L | Flank pain, gross hematuria, and emotional distress | None known | Biopsy + radiotherapy | Died 1.6 months after admitted | 6 cm | Lungs and bladder metastases, 1 month after surgery | IV |
| Antonia et al. (2014) | 57/F/L | Pelvic and back pain | None known | Radical nephrectomy + chemotherapy (adriamycin + ifosfamide and cisplatin) | At least 6 years | 5.5 cm x 4.9 cm | Lungs and brain metastasis, 1 year after surgery | IB |
| Flynn et al. (2015) | 77/F/L | Gross hematuria and flank pain | None known | Radical nephrectomy | At least 2 years | 3.5 cm x 3.2 cm x 3.2 cm | Left colon and adrenal gland | IB |
| Zhang et al. (2018) | 41/M/L | Abdominal distension and gross hematuria | None known | Radical nephrectomy + chemotherapy (ifosfamide + pirarubicin) + Anlotinib | Disease-free at least 26 months | 21 cm x 18 cm x 11 cm | Lungs | IV |

DTIC = dacarbazine, F = female, L = left, M = male, R = right, SAP = serum alkaline phosphatase.?

= Unable to evaluate.
shorter survival times for patients with osteosarcoma were associated with the expression of MSH6 as well as simultaneous nonresponse to chemotherapy and presence of metastasis.\cite{30,30} The FANCF gene is part of the DNA damage repair response, Fanconi anemia-BRCA pathway, which is responsible for DNA repair by homologous recombination and maintenance of genomic stability. We consider this variant to be of unknown significance.

The ERCC4 gene product plays a role in repairing the DNA damage and in maintaining genomic stability. Sun and Li found that ERCC1, 2, and 4 are significantly associated with poor response to chemotherapy and unfavorable survival of osteosarcoma.\cite{31,31} Based on the evidence above, we suspect that this is the reason why this patient is sensitive to chemotherapy and thus has longer survival.

4. Conclusion

The present case illustrates a true primary osteosarcoma originating in the kidney without known clear risk factors. Due to the relatively small number of cases reported in the current literature, there are not enough data to support the early diagnosis and treatment of this tumor. The combination of surgical resection (with the achievement of negative surgical margins) and chemotherapy may be the best current treatment for the disease, compared to surgery or chemotherapy alone, slowing the progression of the disease, reducing the frequency of recurrence, and prolonging the OS.

Author contributions

Investigation: Wei Xiong.

Resources: Changkun Huang, Xuan Zhu, Xiaokun Zhao.

Validation: Xiaokun Zhao.

Writing – original draft: Changkun Huang.

Writing – review & editing: Ran Xu.

References

[1] Flynn KJ, Kaimakiotis HZ, Cheng L, et al. Primary renal extra-osseous osteosarcoma. Can J Urol 2015;22:7929–31.
[2] Haiming RTPF. Osteoblastoma of the kidney histologically identical with osteosarcoma. Arch Pathol 1936:21.
[3] Hamer HG, Washad WNj, Osteosarcoma involving the right kidney. J Urol 1948;60:10–7.
[4] Hudson HC. Osteogenic sarcoma involving the left kidney. J Urol 1956;75:21–4.
[5] Soto PJr, Rader ES, Martin JM, et al. Osteogenic sarcoma of the kidney: report of a case. J Urol 1965;94:532–5.
[6] Johnson LA, Ancona VC, Johnson T, et al. Primary osteosarcoma of the kidney. J Urol 1970;104:528–31.
[7] Chambers A, Carson R, Primary osteosarcoma of the kidney. Br J Radiol 1975;48:316–7.
[8] Axelrod R, Naidech HJ, Myers J, et al. Primary osteosarcoma of the kidney. Cancer 1978;41:724–7.
[9] Biggers R, Stewart J. Primary renal osteosarcoma. Urology 1979;13:674–6.
[10] Bollack C, Cinqualbre J, Warter A, et al. Primary osteosarcoma of the kidney. Br J Urol 1982;54:435–6.
[11] Micolonghi TS, Liang D, Schwartz S. Primary osteogenic sarcoma of the kidney. J Urol 1984;131:1164–6.
[12] Acha Perez M, Llarena Ibaguren R, Albisu Trastan A, et al. Exceptional tumor: primary renal osteosarcoma. Review of 18 cases and report of a new one [in Spanish]. Arch Exp Urol 1993;46:284–7.
[13] Ah-Chong AK, Yip AW. Primary osteogenic sarcoma of the kidney presenting as stage B0 calculus. Br J Urol 1995;71:233–4.
[14] Watson R, Kanowski P, Ades C. Primary osteogenic sarcoma of the kidney. AustNZ J Surg 1995;65:622–3.
[15] Weingartner K, Gerharz EW, Neumann K, et al. Primary osteosarcoma of the kidney. Case report and review of literature. Eur Urol 1995;28:81–4.
[16] Ito K, Tamonogi H, Hasegawa S. A case of primary osteosarcoma of the kidney. Nihon Hinyokika Gakkai zasshi [in Japanese]. Jpn J Urol 1997;88:507–9.
[17] Leventis AK, Stathopoulos GP, Boussettou AC, et al. Primary osteosarcoma of the kidney: a case report and review of the literature. Acta Oncol 1997;36:775–7.
[18] Leggio L, Addolorato G, Abenavoli L, et al. Primary renal angiosarcoma: a rare malignancy. A case report and review of literature. Urol Oncol 2006;24:307–12.
[19] Cioppa T, Marrelli D, Neri A, et al. Primary osteosarcoma of the kidney with retroperitoneal hemorrhage. Case report and review of the literature. Tumori 2007;93:213–6.
[20] Lee S, Lee MR, Lee SJ, et al. Extraosseous osteosarcoma: single institutional experience in Korea.Asia Pac J Clin Oncol 2010;6:126–9.
[21] Puri T, Goyal S, Gupta R, et al. Primary renal osteosarcoma with systemic dissemination. Saudi J Kidney Dis Transpl 2012;23:114–6.
[22] Lopez-Beltran A, Montironi R, Carazo JL, et al. Primary renal osteosarcoma. Am J Clin Pathol 2014;141:747–52.
[23] Wu Y, Yang X, Gao H, et al. Primary osteosarcoma of the kidney: report of a case [in Chinese]. Zhonghua Bing Li Xue Za Zhi 2015;44:412–3.
[24] Virgilio E, Lorenzon L, Stoppacciario A, et al. Primary renal osteosarcoma: a very rare tumour with an ominous prognosis. ANZ J Surg 2017;87:1056–7.
[25] Cancer AJCo. Amin B. Soft tissue sarcoma of the retroperitoneum. AJCC Cancer Staging Manual 8th ed.New York, NY: Springer; 2017.
[26] Mortensen PH, Primary osteogenic sarcoma of the kidney. Br J Urol 1989;63:101–2.
[27] Messen S, Bonkhoff H, Bruch M, et al. Primary renal osteosarcoma. Case report and review of the literature. Urol Int 1995;55:158–61.
[28] Zhang H, Huang JC, Deng Y. Clinicopathologic analysis of primary osteosarcoma of the kidney [in Chinese]. Zhonghua Bing Li Xue Za Zhi 2018;47:629–30.
[29] Skinner DG, Colvin RB, Vermillion CD, et al. Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer 1971;28:1165–77.
[30] Turcotte R. Ueber Metaplasie. Virchows Arch Pathol Anat 1884;97:467–71.
[31] Virchow R. Ueber Metaplasie. Virchows Arch Pathol Anat 1884;97:467–71.